Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07037771 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
A Phase 3 study of Homozygous Familial Hypercholesterolemia, sponsored by Arrowhead Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 16
- Study locations
NCT07037771: Recruiting Phase 3 study of Homozygous Familial Hypercholesterolemia, sponsored by Arrowhead Pharmaceuticals.
NCT07037771 is a Phase 3 study of Homozygous Familial Hypercholesterolemia that is actively recruiting participants, run by Arrowhead Pharmaceuticals. The registered enrollment target is 60 participants, below the 242-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (75% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07037771, a Phase 3 study of Homozygous Familial Hypercholesterolemia, is actively recruiting participants, sponsored by Arrowhead Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 16
- Study locations
Study Summary
This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG zodasiran Injection
Study Locations (16)
Other
- Research Site 10 - Jerusalem
- Research Site 15 - Tel Litwinsky
- Research Site 12 - Christchurch
- Research Site 8 - Cape Town
New South Wales
- Research Site 13 - Camperdown
- Research Site 9 - Saint Leonards
Quebec
- Research Site 6 - Chicoutimi
- Research Site 4 - Québec
Illinois
- Research Site 7 - Park Ridge
New York
- Research Site 2 - New York
Ohio
- Research Site 1 - Cincinnati
Pennsylvania
- Research Site 14 - Pittsburgh
Western Australia
- Research Site 3 - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2027-08-20 |
| Phase | Phase 3 |
What NCT07037771 shows while recruiting
NCT07037771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 242-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Homozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07037771 lists 16 locations in 11 states (Other, New South Wales, Quebec).
Frequently Asked Questions
What is clinical trial NCT07037771 about?
NCT07037771 is a clinical study titled "A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)". This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (...
What is the current status of trial NCT07037771?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-06-17. Estimated completion is 2027-08-20.
What conditions does trial NCT07037771 study?
This clinical trial studies the following conditions: Homozygous Familial Hypercholesterolemia.
What interventions are being tested in trial NCT07037771?
The interventions under investigation include: Placebo (DRUG), zodasiran Injection (DRUG).
Who is sponsoring clinical trial NCT07037771?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07037771 being conducted?
This trial has 16 study locations across Illinois, New York, Ohio, Pennsylvania, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homozygous Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
COMPLETED · Phase 3
-
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
RECRUITING
-
HoFH, the International Clinical Collaborators Registry
RECRUITING
-
LOWER: Lomitapide Observational Worldwide Evaluation Registry
RECRUITING
-
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI